Science Reviewer/Advisor

Al Corey has over 37 years of experience in the pharmaceutical industry, including work as an independent consultant. As a consultant he offered preclinical and clinical pharmacokinetic, pharmacodynamic, and pharmacometric support services, with emphasis on providing strategic planning services throughout a compound’s development life cycle.
Al has worked for a variety of large and small pharmaceutical companies: he started in 1980 at Norwich Eaton Pharmaceuticals, which was acquired by Proctor & Gamble Pharmaceuticals. In 1997, he moved to Otsuka America Pharmaceuticals, and from there joined Human Genome Sciences in 2002. Human Genome Sciences was acquired by GlaxoSmithKline in 2012, and Al then joined that company. After joining Parexel International in 2015, Al formed AC Pharmaco, LLC (acpharmaco@gmail.com) in 2016, and retired from that role in October 2019. Al formed AC Thera, LLC (al.corey@ac-thera.com) in 2018 to pursue the development of nanobodies that neutralize bacterial toxins (Patent No. 16/210,080) as therapeutic options for unmet medical needs; these activities are ongoing.
During his career, Al worked on drugs from a variety of therapeutic areas, including the anti-infective, anti-inflammatory, oncology, cardiovascular, renal, antiviral, immunomodulatory, and bioterrorism arenas. Beginning with his tenure at Human Genome Sciences, Al’s work experiences have primarily centered on the development of monoclonal antibodies. He has supported numerous IND, BLA, and NDA filings and has contributed to ex-US regulatory filings.

Work Terms

I am interested in part-time work. My hourly rate is flexible, but is usually $250/hour.